Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 6 (2024)

Timing of cardio-oncological rehabilitation and cardiorespiratory fitness in patients receiving cardiotoxic chemotherapy: a longitudinal observational study

  • Caroline Schneider
  • Annika Dierks
  • Manuela Rabaglio
  • Kristin L. Campbell
  • Matthias Wilhelm
  • Prisca Eser
DOI
https://doi.org/10.57187/s.3588
Cite this as:
Swiss Med Wkly. 2024;154:3588
Published
17.06.2024

Summary

AIMS: Anthracycline-based chemotherapy has well-known cardiotoxic effects, butmay also cause skeletal muscle myopathy and negatively affect cardiorespiratory fitness and quality of life. The effectiveness of exercise training in improving cardiorespiratory fitness and quality of life during chemotherapy is highly variable. We set out to determine how the effect of exercise training on cardiorespiratory fitness (primary outcome) and quality of life (secondary outcome) in cancer patients is affected by the type of therapy they receive (cardiotoxic therapy with or without anthracyclines; non-cardiotoxic therapy) and the timing of the exercise training (during or after therapy).

METHODS: Consecutive patients with cancer who participated in an exercise-based cardio-oncology rehabilitation programme at a university hospital in Switzerland between January 2014 and February 2022 were eligible. Patients were grouped based on chemotherapy (anthracycline vs non-anthracycline) and timing of exercise training (during vs after chemotherapy). Peak oxygen uptake (VO2) was assessed with cardiopulmonary exercise testing (n = 200), and quality of life with the Functional Assessment of Cancer Therapies questionnaire (n = 77). Robust linear models were performed for change in peak VO2 including type and timing of cardiotoxic therapies, age, training impulse and baseline peak VO2; change in quality of life was analysed with cumulative linked models.

RESULTS: In all patients with valid VO2 (n = 164), median change in peak VO2 from before to after exercise training was 2.3 ml/kg/min (range: –10.1–15.9). The highest median change in peak VO2 was 4.1 ml/kg/min (interquartile range [IQR]: 0.7–7.7) in patients who completed exercise training during non-anthracycline cardiotoxic or non-cardiotoxic therapies, followed by 2.8 ml/kg/min (IQR: 1.2–5.3) and 2.3 ml/kg/min (IQR: 0.1–4.6) in patients who completed exercise training after anthracycline and after non-anthracycline cardiotoxic or non-cardiotoxic therapies, respectively. In patients who completed exercise training during anthracycline therapy, peak VO2 decreased by a median of –2.1 ml/kg/min (IQR: –4.7–2.0). In the robust linear model, there was a significant interaction between type and timing of cancer treatment for anthracycline therapy, with greater increases in peak VO2 when exercise training was performed after anthracycline therapy. For quality of life, higher baseline scores were negatively associated with changes in quality of life.

CONCLUSION: In our cohort, the increase in cardiorespiratory fitness was diminished when exercise training was performed concurrently with anthracyclines. For patients with cardiotoxic treatments other than anthracyclines, cardiorespiratory fitness and quality of life was not associated with timing of exercise training.

References

  1. Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, et al. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol. 2014 Sep;64(13):1310–9. 10.1016/j.jacc.2014.07.948 DOI: https://doi.org/10.1016/j.jacc.2014.07.948
  2. Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012 Jul;30(20):2530–7. 10.1200/JCO.2011.39.9014 DOI: https://doi.org/10.1200/JCO.2011.39.9014
  3. Lipshultz SE, Landy DC, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol. 2012 Apr;30(10):1050–7. 10.1200/JCO.2010.33.7907 DOI: https://doi.org/10.1200/JCO.2010.33.7907
  4. Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. Eur Heart J Qual Care Clin Outcomes. 2020 Oct;6(4):315–22. 10.1093/ehjqcco/qcaa015 DOI: https://doi.org/10.1093/ehjqcco/qcaa015
  5. Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol. 2015 Feb;26(2):272–8. 10.1093/annonc/mdu250 DOI: https://doi.org/10.1093/annonc/mdu250
  6. Rausch V, Sala V, Penna F, Porporato PE, Ghigo A. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis. 2021 Jan;10(1):1. 10.1038/s41389-020-00288-6 DOI: https://doi.org/10.1038/s41389-020-00288-6
  7. Campelj DG, Goodman CA, Rybalka E. Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere. Cancers (Basel). 2021 Jul;13(14):3615. 10.3390/cancers13143615
  8. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep;37(36):2768–801. 10.1093/eurheartj/ehw211 DOI: https://doi.org/10.1093/eurheartj/ehw211
  9. Klassen O, Schmidt ME, Scharhag-Rosenberger F, Sorkin M, Ulrich CM, Schneeweiss A, et al. Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy. Acta Oncol. 2014 Oct;53(10):1356–65. 10.3109/0284186X.2014.899435 DOI: https://doi.org/10.3109/0284186X.2014.899435
  10. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep;64(9):938–45. 10.1016/j.jacc.2014.06.1167 DOI: https://doi.org/10.1016/j.jacc.2014.06.1167
  11. Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev. 2015;2015:795602. 10.1155/2015/795602 DOI: https://doi.org/10.1155/2015/795602
  12. Campelj DG, Goodman CA, Rybalka E. Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere. Cancers (Basel). 2021 Jul;13(14):3615. 10.3390/cancers13143615 DOI: https://doi.org/10.3390/cancers13143615
  13. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330–52. 10.1016/j.pcad.2006.10.002 DOI: https://doi.org/10.1016/j.pcad.2006.10.002
  14. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229-4361. DOI: https://doi.org/10.1093/eurheartj/ehac244
  15. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019 May;139(21):e997–1012. 10.1161/CIR.0000000000000679 DOI: https://doi.org/10.1161/CIR.0000000000000679
  16. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018 Aug;36(22):2297–305. 10.1200/JCO.2017.77.5809 DOI: https://doi.org/10.1200/JCO.2017.77.5809
  17. Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, et al. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist. 2011;16(1):112–20. 10.1634/theoncologist.2010-0197 DOI: https://doi.org/10.1634/theoncologist.2010-0197
  18. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al.; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8–30. 10.1093/annonc/mdv298 DOI: https://doi.org/10.1093/annonc/mdv298
  19. Corrà U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur J Heart Fail. 2014 Sep;16(9):929–41. 10.1002/ejhf.156 DOI: https://doi.org/10.1002/ejhf.156
  20. Cella D. Assessment methods for quality of life in cancer patients: the FACIT measurement system. Int J Pharm Med. 2000;14(2):78–81. 10.2165/00124363-200004000-00007 DOI: https://doi.org/10.1097/00124363-200004000-00007
  21. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002 Dec;24(6):547–61. 10.1016/S0885-3924(02)00529-8 DOI: https://doi.org/10.1016/S0885-3924(02)00529-8
  22. Burnham TR, Wilcox A. Effects of exercise on physiological and psychological variables in cancer survivors. Med Sci Sports Exerc. 2002 Dec;34(12):1863–7. 10.1097/00005768-200212000-00001 DOI: https://doi.org/10.1097/00005768-200212000-00001
  23. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003 May;21(9):1660–8. 10.1200/JCO.2003.04.093 DOI: https://doi.org/10.1200/JCO.2003.04.093
  24. Herrero F, San Juan AF, Fleck SJ, Balmer J, Pérez M, Cañete S, et al. Combined aerobic and resistance training in breast cancer survivors: A randomized, controlled pilot trial. Int J Sports Med. 2006 Jul;27(7):573–80. 10.1055/s-2005-865848 DOI: https://doi.org/10.1055/s-2005-865848
  25. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007 Oct;25(28):4396–404. 10.1200/JCO.2006.08.2024 DOI: https://doi.org/10.1200/JCO.2006.08.2024
  26. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009 Jan;27(3):344–51. 10.1200/JCO.2007.15.4963 DOI: https://doi.org/10.1200/JCO.2007.15.4963
  27. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017 Jan;52:91–104. 10.1016/j.ctrv.2016.11.010
  28. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006 Jul;175(1):34–41. 10.1503/cmaj.051073 DOI: https://doi.org/10.1503/cmaj.051073
  29. Lakoski SG, Willis BL, Barlow CE, Leonard D, Gao A, Radford NB, et al. Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. JAMA Oncol. 2015 May;1(2):231–7. 10.1001/jamaoncol.2015.0226 DOI: https://doi.org/10.1001/jamaoncol.2015.0226
  30. Laukkanen JA, Zaccardi F, Khan H, Kurl S, Jae SY, Rauramaa R. Long-term Change in Cardiorespiratory Fitness and All-Cause Mortality: A Population-Based Follow-up Study. Mayo Clin Proc. 2016 Sep;91(9):1183–8. 10.1016/j.mayocp.2016.05.014 DOI: https://doi.org/10.1016/j.mayocp.2016.05.014
  31. Kirkham AA, Lloyd MG, Claydon VE, Gelmon KA, McKenzie DC, Campbell KL. A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training. Oncologist. 2019 Feb;24(2):273–84. 10.1634/theoncologist.2018-0049 DOI: https://doi.org/10.1634/theoncologist.2018-0049
  32. Bjørke AC, Sweegers MG, Buffart LM, Raastad T, Nygren P, Berntsen S. Which exercise prescriptions optimize V̇O2 max during cancer treatment?-A systematic review and meta-analysis. Scand J Med Sci Sports. 2019 Sep;29(9):1274–87. 10.1111/sms.13442 DOI: https://doi.org/10.1111/sms.13442
  33. Kampshoff CS, Chinapaw MJ, Brug J, Twisk JW, Schep G, Nijziel MR, et al. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. BMC Med. 2015 Oct;13(1):275. 10.1186/s12916-015-0513-2 DOI: https://doi.org/10.1186/s12916-015-0513-2
  34. van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, et al. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol. 2015 Jun;33(17):1918–27. 10.1200/JCO.2014.59.1081 DOI: https://doi.org/10.1200/JCO.2014.59.1081
  35. Huang G, Wang R, Chen P, Huang SC, Donnelly JE, Mehlferber JP. Dose-response relationship of cardiorespiratory fitness adaptation to controlled endurance training in sedentary older adults. Eur J Prev Cardiol. 2016 Mar;23(5):518–29. 10.1177/2047487315582322 DOI: https://doi.org/10.1177/2047487315582322
  36. Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the Prevention of Anthracycline-induced Functional Disability and Cardiac Dysfunction: The BReast Cancer Randomized EXercise InTervention (BREXIT) Study. Circulation. 2023;147(7): 532–45. 10.1161/CIRCULATIONAHA.122.062814 DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.062814
  37. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020 Dec;54(24):1451–62. 10.1136/bjsports-2020-102955 DOI: https://doi.org/10.1136/bjsports-2020-102955
  38. Medicine ACoS. ACSM’s guidelines for exercise testing and prescription testing and prescription. 6th ed. Baltimore: ACSM2000.
  39. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993 Jan;25(1):71–80. 10.1249/00005768-199301000-00011 DOI: https://doi.org/10.1249/00005768-199301000-00011

Most read articles by the same author(s)